(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -53.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Stoke Therapeutics's revenue in 2025 is $190,908,000.On average, 5 Wall Street analysts forecast STOK's revenue for 2025 to be $8,443,195,909, with the lowest STOK revenue forecast at $4,454,563,029, and the highest STOK revenue forecast at $10,127,729,402. On average, 3 Wall Street analysts forecast STOK's revenue for 2026 to be $2,196,215,865, with the lowest STOK revenue forecast at $873,550,784, and the highest STOK revenue forecast at $3,804,313,664.
In 2027, STOK is forecast to generate $2,135,449,488 in revenue, with the lowest revenue forecast at $873,550,784 and the highest revenue forecast at $3,927,702,713.